New study aims to personalize depression treatment with escitalopram

NCT ID NCT07480525

Not yet recruiting Symptom relief Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well and safely the antidepressant escitalopram works in people experiencing their first episode of major depression who have never taken medication for it. Two hundred adults aged 18 to 65 will take escitalopram for 8 weeks, and researchers will track their symptoms, thinking abilities, and side effects. The goal is to find out who benefits most and understand the biological reasons behind the drug's effects, paving the way for more personalized depression care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Hebei Provincial Mental Health Center

Baoding, Hebei, 071000, China
Peking University Sixth Hostipal

Beijing, Beijing Municipality, 100191, China
Shandong Mental Health Center

Jinan, Shandong, 250014, China
The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, 110001, China
The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.